208 related articles for article (PubMed ID: 34690785)
1. Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries.
Gozzo L; Romano GL; Romano F; Brancati S; Longo L; Vitale DC; Drago F
Front Pharmacol; 2021; 12():755052. PubMed ID: 34690785
[TBL] [Abstract][Full Text] [Related]
2. Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries.
Gozzo L; Romano GL; Brancati S; Cicciù M; Fiorillo L; Longo L; Vitale DC; Drago F
Front Pharmacol; 2021; 12():823199. PubMed ID: 35185551
[TBL] [Abstract][Full Text] [Related]
3. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
4. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.
Gonçalves E
Eur J Health Econ; 2020 Apr; 21(3):311-320. PubMed ID: 31919703
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries.
Gozzo L; Romano GL; Brancati S; Longo L; Vitale DC; Drago F
Front Pharmacol; 2023; 14():1169400. PubMed ID: 37188269
[TBL] [Abstract][Full Text] [Related]
6. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
7. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
8. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
[TBL] [Abstract][Full Text] [Related]
9. Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.
Qiu T; Liang S; Wang Y; Dussart C; Borissov B; Toumi M
Front Public Health; 2021; 9():754482. PubMed ID: 34900902
[TBL] [Abstract][Full Text] [Related]
10. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England.
Ten Ham RMT; Frederix GWJ; Wu O; Goettsch W; Leufkens HGM; Klungel OH; Hoekman J
Value Health; 2022 Mar; 25(3):390-399. PubMed ID: 35227451
[TBL] [Abstract][Full Text] [Related]
11. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.
Jönsson B; Hampson G; Michaels J; Towse A; von der Schulenburg JG; Wong O
Eur J Health Econ; 2019 Apr; 20(3):427-438. PubMed ID: 30229376
[TBL] [Abstract][Full Text] [Related]
12. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
13. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
[TBL] [Abstract][Full Text] [Related]
14. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
15. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
16. Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations.
Madrid Paredes J; Versteeg JW; Vreman RA; Bloem LT
Clin Pharmacol Ther; 2024 Jul; 116(1):136-146. PubMed ID: 38505926
[TBL] [Abstract][Full Text] [Related]
17. Advanced therapy medicinal products: current and future perspectives.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
[TBL] [Abstract][Full Text] [Related]
18. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.
Rejon-Parrilla JC; Espin J; Garner S; Kniazkov S; Epstein D
Front Pharmacol; 2023; 14():1199500. PubMed ID: 38089054
[No Abstract] [Full Text] [Related]
19. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
Chassagnol F; Marcelli G; Wagle J; Giuliani G; Traub D; Schaub V; Ruof J
Health Policy; 2020 Sep; 124(9):943-951. PubMed ID: 32622542
[TBL] [Abstract][Full Text] [Related]
20. Cell-based medicinal products approved in the European Union: current evidence and perspectives.
Bellino S; La Salvia A; Cometa MF; Botta R
Front Pharmacol; 2023; 14():1200808. PubMed ID: 37583902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
